Preclinical research reports that CUDC-907 can improve temozolomide activity in glioblastoma by combining dual PI3K and HDAC inhibition. The study focuses on resistance mechanisms that limit standard chemotherapy effectiveness and evaluates whether the combination can disrupt tumor survival pathways that sustain recurrent disease. CUDC-907 is positioned as a targeted approach intended to sensitize temozolomide-treated tumors—especially in acquired-resistant settings. The results add to a broader effort to use mechanistically grounded combinations to expand TMZ’s clinical utility in difficult-to-treat brain tumors. For developers, the work highlights PI3K/epigenetic axis modulation as a potential strategy worth further translation, particularly where temozolomide resistance is expected to dominate outcomes.